Skip to main content
SpringerLink
Log in

Pre-therapeutic dosimetry with radiolabelled somatostatin analogues in patients with advanced neuroendocrine tumours

  • Letter to the Editor
  • Published:
European Journal of Nuclear Medicine and Molecular Imaging Aims and scope Submit manuscript

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Reubi JC, Schar JC, Waser B, Wenger S, Heppeler A, Schmitt JS, et al. Affinity profiles for human somatostatin receptor subtypes SST1-SST5 of somatostatin radiotracers selected for scintigraphic and radiotherapeutic use. Eur J Nucl Med 2000;27(3):273–82.

    Article  CAS  PubMed  Google Scholar 

  2. Froidevaux S, Heppeler A, Eberle AN, Meier AM, Hausler M, Beglinger C, et al. Preclinical comparison in AR4-2J tumor-bearing mice of four radiolabeled 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid-somatostatin analogs for tumor diagnosis and internal radiotherapy. Endocrinology 2000;141(9):3304–12.

    Article  Google Scholar 

  3. Waldherr C, Pless M, Maecke H, Schumacher T, Crazzolara A, Nitzsche E, et al. Tumor response and clincical benefit in neuroendocrine tumors after 7.4 GBq 90Y-DOTATOC. J Nucl Med 2002;43:610–6.

    CAS  PubMed  Google Scholar 

  4. Paganelli G, Bodei L, Handkiewicz Junak D, Rocca P, Papi S, Lopera Sierra M, et al. 90Y-DOTA-d-Phe1-Try3-octreotide in therapy of neuroendocrine malignancies. Biopolymers 2002;66:393–8.

    Article  Google Scholar 

  5. Otte A, Herrmann R, Heppeler A, Behe M, Jermann E, Powell P, et al. Yttrium-90 DOTATOC: first clinical results. Eur J Nucl Med 1999;26:1439–47.

    Article  CAS  PubMed  Google Scholar 

  6. Waldherr C, Pless M, Maecke HR, Haldemann A, Mueller-Brand J. The clinical value of [90Y-DOTA]-d-Phe1-Tyr3-octreotide (90Y-DOTATOC) in the treatment of neuroendocrine tumours: a clinical phase II study. Ann Oncol 2001;12(7):941–5.

    Article  CAS  PubMed  Google Scholar 

  7. Kwekkeboom D, Bakker W, Kam BLR, Teunissen J, Kooij P, Herder W, et al. Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0, Tyr3]octreotate. Eur J Nucl Med Mol Imaging 2003;30:417–22.

    CAS  PubMed  Google Scholar 

  8. Konijnenberg MW. Is the renal dosimetry for [90Y-DOTA0,Tyr3]octreotide accurate enough to predict thresholds for individual patients? Cancer Biother Radiopharm 2003;18(4):619–25.

    Article  Google Scholar 

  9. Teunissen J, Kwekkeboom D, Krenning E. Quality of life in patients with gastro-entero- pancreatic tumors treated with [177Lu- DOTA0,Tyr3]octreotate. J Clin Oncol 2004;22:2724–9.

    Article  Google Scholar 

  10. Jamar F, Barone R, Mathieu I, Walrand S, Labar D, Carlier P, et al. 86Y-DOTA0-d-Phe1-Tyr3-octreotide (SMT 487)—a phase 1 clinical study: pharmacokinetics, biodistribution and renal protective effect of different regimens of amino acid co-infusion. Eur J Nucl Med Mol Imaging 2003;30:510–8.

    CAS  PubMed  Google Scholar 

  11. De Jong M, Valkema R, Van Gameren A, Van Boven H, Bex A, Van De Weyer EP, et al. Inhomogeneous localization of radioactivity in the human kidney after injection of [111In-DTPA]octreotide. J Nucl Med 2004;45(7):1168–71.

    Google Scholar 

  12. Moll S, Nickeleit V, Mueller-Brand J, Brunner FP, Maecke HR, Mihatsch MJ. A new cause of renal thrombotic microangiopathy: yttrium-90-DOTATOC internal radiotherapy. Am J Kidney Dis 2001;37(4):847–51.

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Institute of Nuclear Medicine, University Hospital Basel, Petersgraben 4, 4031, Basel, Switzerland

    F. Forrer & J. Mueller-Brand

  2. Division of Radiological Chemistry, University Hospital Basel, Basel, Switzerland

    H. Maecke

Authors
  1. F. Forrer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. J. Mueller-Brand
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. H. Maecke
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to F. Forrer.

Additional information

An authors’ reply to this letter is available at http://dx.doi.org/10.1007/s00259-004-1727-2

Rights and permissions

Reprints and permissions

About this article

Cite this article

Forrer, F., Mueller-Brand, J. & Maecke, H. Pre-therapeutic dosimetry with radiolabelled somatostatin analogues in patients with advanced neuroendocrine tumours. Eur J Nucl Med Mol Imaging 32, 511–512 (2005). https://doi.org/10.1007/s00259-004-1726-3

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00259-004-1726-3

Keywords

Search

Navigation